Myelodysplastic Syndromes (MDS) Clinical Trial
— Aza-EOfficial title:
A Single Arm Pilot Study of Azacitidine in Myelodysplastic Syndrome / Acute Myeloid Leukaemia, With Eltrombopag Support for Thrombocytopenia.
Myelodysplastic Syndrome (MDS) is a disease of the bone marrow characterized by
anemia,neutropenia, and thrombocytopenia (low red blood cell, white blood cell, and platelet
counts). MDS patients with thrombocytopenia who fail standard therapies require regular
platelet transfusions which are expensive and inconvenient, and are a risk for further
serious bleeding complications. The new treatment of MDS using azacitidine has shown to
increase the survival rate of MDS patients including to improve platelet production over
time. However,in the early cycles of treatment with azacitidine,the low platelet counts tend
to exacerbate before they provide any clinical benefit.
Eltrombopag is a drug designed to activate the thrombopoietin receptor. Eltrombopag has been
able to increase platelet counts in healthy Thrombocytopenia Purpura (ITP), a disease where
patients destroy their own platelets very rapidly and thus develop thrombocytopenia.
Eltrombopag is administered orally and is Therapeutic Goods Administration (TGA) approved
for the treatment of thrombocytopenia in patients with chronic ITP who failed to respond to
standard treatment.
This study is a single arm pilot study to evaluate the safety and tolerability of
Eltrombopag in the treatment of low platelet counts in adult subjects with MDS treated using
azacitidine This study also incorporates a correlative laboratory component designed to
determined the mechanism of action of 5-azacitidine +/- Eltrombopag and to determine a
baseline profile which may predict those most responsive. These studies will incorporate
gene methylation and expression, and immunoprofiling.
Status | Completed |
Enrollment | 25 |
Est. completion date | May 2015 |
Est. primary completion date | May 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients with low platelet count (<=150 x109/L)and in addition disease diagnosis of either MDS, or nonproliferative CMML or low marrow blast count AML not suitable for induction chemotherapy - Age >18 years - ECOG score 0-2 at screening - Life expectancy =12 weeks - Ability to comply with the adequate contraception in patients of childbearing potential. Exclusion Criteria: - Subjects with the diagnosis acute promyelocytic leukaemia - Prior treatment with azacitidine or any other methyl-transferase inhibitor (e.g. decitabine) - Prior treatment with eltrombopag, romiplostim, or other TPO-receptor agonist - AML or MDS requiring cytoreductive therapy (eg hydroxyurea, ara-c, thioguanine etc) in the month prior to study entry - Known uncontrolled medical conditions which may compromise participation in this study including but not limited to: - Poorly controlled congestive heart failure: ejection fraction <30% measured in past 6 months) or NYHA class IV - Arrhythmia known to increase the risk of thromboembolic events. - Unstable angina or an ischaemic cardiac event requiring hospital admission in the previous 12 months. - Unresolved GI disease that may significantly alter the absorption of eltrombopag - Known pro-thrombotic condition as defined by a history =1 unprovoked deep venous thrombosis or pulmonary embolism, or any DVT/PE with a procoagulant condition screen suggesting the presence of a procoagulant condition (prothrombin gene mutation homozygosity, factor V leiden homozygosity, antithrombin deficiency, lupus anticoagulant syndrome). - History of Ischaemic neurological event (TIA or stroke) within the preceding 2 years. - Inadequate renal function (eGFR <30 ml/min by Cockcroft-Gault (C-G) formula, or as measured by 24 hour urinary creatinine clearance) - Inadequate hepatic function: - bilirubin =1.5xULN - =80µmol/L acceptable if attributed to haemolysis, ineffective erythropoiesis or iron overload). This applies also for patients with Gilbert's Syndrome. - AST or ALT =2xULN (=3xULN acceptable if attributed to transfusion-associated iron overload) - Patients with known liver cirrhosis. - Other concurrent severe and/or uncontrolled medical conditions including a history of malignancy other than MDS/AML in the preceding 2 years requiring chemotherapy and/or radiotherapy. Non melanotic skin cancers requiring low dose local radiotherapy or topical agents are allowed on study if considered clinically stable or healed. - Women who are pregnant or breast-feeding. - Treatment with growth factors such as erythropoietin, GCSF or stem cell factor in the 21 days prior to commencement of study therapy. - Active or uncontrolled infections. - Subjects with known HIV infection. - Has any other clinically important abnormalities as determined by the investigator that may interfere with his or her participation in or compliance with the study - Bone marrow fibrosis that leads to an inability to aspirate marrow for quality cytological assessment, termed a "dry tap". - Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule. This condition must be discussed with the patient prior to signing consent and registration in the trial. - Splenomegaly >14cm on the screening ultrasound examination. |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Australia | Peter MacCallum Cancer Centre | East Melbourne | Victoria |
Australia | Cabrini Hospital | Malvern | Victoria |
Lead Sponsor | Collaborator |
---|---|
Peter MacCallum Cancer Centre, Australia | Celgene Corporation, GlaxoSmithKline |
Australia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of events of non-haematological toxicities related to the combination of eltrombopag and azacitidine | The number of events of Grade III/IV non-haematological toxicities will be measured based on the possibly, probably or definitely relatedness to the combination of eltrombopag and azacitidine | At 6 cycles of therapy (approx 6 months) | Yes |
Secondary | Number of patients with improved platelet counts and the dose at which this may be achieved. | Approximately 2.5 years after the last accrued patient completes study treatment | No | |
Secondary | Correlation of the laboratory findings with the response of the combination of 5-azacitidine and eltrombopag in patients with MDS and low marrow blast count AML | Approximately 2.5 years after last accrued patient completes study treatment | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02550535 -
A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients
|
Phase 1/Phase 2 | |
Completed |
NCT00186342 -
Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies
|
N/A | |
Completed |
NCT00528983 -
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
|
Phase 1 | |
Completed |
NCT01355913 -
Screening and Genetic Monitoring of Patients With Myelodysplastic Syndromes (MDS) Under Different Treatment Modalities by Cytogenetic Analyses of Circulating CD34+Cells
|
||
Withdrawn |
NCT04985656 -
A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes
|
Phase 2 | |
Completed |
NCT01736683 -
Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)
|
Phase 2 | |
Completed |
NCT02333058 -
Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies
|
Phase 2 | |
Completed |
NCT01135849 -
B-Receptor Signaling in Cardiomyopathy
|
N/A | |
Withdrawn |
NCT04395092 -
Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)
|
Phase 2 | |
Completed |
NCT01885897 -
IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT
|
Phase 1/Phase 2 | |
Recruiting |
NCT05092451 -
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
|
Phase 1/Phase 2 | |
Recruiting |
NCT05884333 -
Cord Blood Transplant in Adults With Blood Cancers
|
Phase 2 | |
Completed |
NCT02390414 -
The Myelodysplasia Transplantation-Associated Outcomes (MDS-TAO) Study
|
||
Completed |
NCT01326377 -
ON 01910.Na for Intermediate1-2, or High Risk Trisomy 8 Myelodysplastic Syndrome (MDS)
|
Phase 2 | |
Completed |
NCT02966782 -
A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)
|
Phase 1 | |
Recruiting |
NCT02779569 -
A Clinical Trial Evaluating the Efficacy of Ultra Low Dose of Decitabine in Myelodysplastic Syndromes (MDS)
|
N/A | |
Recruiting |
NCT02099669 -
Red Blood Cell Transfusion Thresholds and QOL in MDS
|
N/A | |
Completed |
NCT01392989 -
Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders
|
Phase 2 | |
Not yet recruiting |
NCT06398457 -
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
|
Early Phase 1 | |
Recruiting |
NCT02775383 -
The National Myelodysplastic Syndromes (MDS) Study
|